Rare Cannabinoid Company Expands Focus Beyond CBD With Targeted Hemp Products in Hawaii

The evolution of the hemp-derived cannabinoid market has been rapid and unpredictable since the 2018 Farm Bill, with thousands of companies jumping into the CBD craze. While most brands raced to capitalize on CBD’s popularity, founders Jennifer Carlile and Jared Dalgamouni in Hawaii took a different path. Their curiosity about what comes after CBD led to the creation of the Rare Cannabinoid Company, a brand dedicated to exploring the lesser-known compounds in the cannabis plant. According to High Times, this initiative began after customers of their original company, Hawaiian Choice, started inquiring about cannabinoids such as CBN and CBG

Carlile and Dalgamouni recognized early on that the cannabis plant contains over a hundred cannabinoids, many of which have unique properties and potential benefits. “As we began studying rare cannabinoids, it became clear that they could potentially be even more effective for certain needs,” said Carlile. This realization prompted them to develop formulations tailored to specific wellness outcomes, such as improved sleep, relief from soreness, or enhanced mood, rather than relying solely on CBD. The Rare Cannabinoid Company officially launched in 2020, coinciding with the onset of the COVID-19 pandemic, and quickly distinguished itself by offering products built around a variety of cannabinoids including CBN, CBG, THCV, and CBDV

Education has become a cornerstone of Rare Cannabinoid Company's mission, as public awareness of rare cannabinoids lagged behind scientific research. The company has published hundreds of educational blog posts and collaborated with clinicians and retailers to bridge the knowledge gap. “The science has been there for quite some time. Public awareness has just been slower to catch up,” Carlile explained. To help customers navigate the complex world of cannabinoids, the company developed interactive tools like the Cannabinoid Finder Quiz, which recommends products based on users' needs and preferences

Operating from Hawaii, the company integrates local values and agricultural excellence into its operations. Carlile likens the quality of Hawaiian-grown hemp to the reputation of Kona coffee, emphasizing the unique environmental conditions—volcanic soil, tropical rains, and high elevation—that contribute to superior crops. “Our CBD comes from hemp grown on the slopes of Haleakalā, nourished by volcanic soil, rain, and sunshine,” she said. Coupled with cGMP-certified manufacturing and rigorous third-party lab testing, their products blend island-grown ingredients with cutting-edge cannabinoid science

Despite the influx of chemically converted cannabinoids and shifting federal regulations, Rare Cannabinoid Company maintains a focus on plant-derived compounds and high transparency. Many of their offerings are THC-free, while others contain low THC doses to ensure a gentle effect. Carlile expressed hope that regulations will continue to allow low-to-moderate dose THC products, stating, “Our hope is that low-to-moderate dose THC products—around 2.5 to 5 milligrams per serving—will continue to be allowed.” As larger companies enter the rare cannabinoid space and consumer interest grows, the founders remain optimistic that rare cannabinoids will become a staple of wellness routines

From the OG Lab perspective, the journey of Rare Cannabinoid Company highlights the industry’s shift toward a more nuanced understanding of the cannabis plant’s potential. As regulatory frameworks evolve and scientific research advances, brands that prioritize education, quality, and transparency are likely to shape the future landscape. The ongoing exploration of rare cannabinoids signals a broader trend that could redefine how consumers approach plant-based wellness in the years ahead